Natco Pharma to invest $14 mn in US-based biotechnology firm eGenesis Inc
Natco Pharma on Tuesday said it is investing USD 14 million (over Rs 130 crore) in eGenesis Inc, a US-based biotechnology firm, through its two subsidiaries.
As part of the transaction, Natco Pharma (Canada) Inc will invest USD 9.5 million and Natco Pharma South Africa Proprietary Ltd USD 4.5 million in eGenesis through convertible promissory notes, the Hyderabad-based company said in a regulatory filing. eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure, it added.
In 2024, Natco Pharma had invested USD 8 million in eGenesis, Inc through preferred stock.
The total investment made by it in eGenesis, Inc now stands at USD 22 million, the company said.
The eGenesis Genome Engineering and Production (EGEN) platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via ..
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.business-standard.com — the content belongs to Business Standard.
